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In ThIs Issue
•	 Patients selected for 
Definitive Concurrent 
Chemoradiation at high-
Volume Facilities Achieve 
Improved survival in stage 
III non–small-Cell Lung 
Cancer
The authors sought to determine the relationship 
between facility case volume and overall survival 
in patients with stage III non-small cell lung 
cancer (NSCLC) treated with definitive concurrent 
chemoradiation (CCRT). The analysis of 10,072 stage 
III NSCLC patients from the National Cancer Data Base 
(2004–2006), who were treated with definitive CCRT to 
59.4–74.0 Gy, revealed that 12% of them were treated 
at high volume facilities (HVF). HVF were facilities in 
the 90th percentile of annual CCRT volume (≥12 cases/
year). HVF patients demonstrated a higher Charlson–
Deyo comorbidity score, with more advanced nodal 
stage, had higher doses, and 3D-conformal or intensity-
modulated radiotherapy. Treatment at HVF was 
independently correlated with a significantly lower risk 
of death, when adjusted for demographic and clinical 
covariates including academic affiliation (hazards ratio 
[HR] = 0.93; p = 0.03). The results were confirmed with 
propensity score matching (HR = 0.91; p = 0.04). These 
findings suggest that CCRT at HVF is associated with 
superior overall survival of stage III NSCLC patients, 
independent of academic affiliation. (p. 937)
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•	 upregulation of PD-L1 by 
eGFR Activation Mediates 
the Immune escape in 
eGFR-Driven nsCLC: 
Implication for Optional 
Immune Targeted Therapy 
for nsCLC Patients with 
eGFR Mutation
blood mononuclear cell co-culture system. The results 
demonstrated that PD-L1 expression was induced by 
EGFR activation, exon 19 deletions, and L858R mutation. 
PD-L1 was upregulated by EGFR activation through the 
p-ERK1/2/p-c-Jun but not p-AKT/p-S6 pathway. This 
in turn could trigger the PD-L1/PD-1 axis that leads to 
T cell apoptosis in tumor cells and a peripheral blood 
mononuclear cell co-culture system. EGFR-TKI reversed 
T cell suppression and increased interferon-γproduction. 
However, the combination treatment with EGFR-TKIs and 
an anti-PD-1 antibody was not synergistic in the co-culture 
system. This study demonstrated that EGFR-TKIs could 
directly suppress tumor cell viability and indirectly 
increase antitumor immunity via downregulation of 
PD-L1. Although no synergy was observed with the 
combination treatment in NSCLC, anti-PD-1/PD-L1 
antibodies could potentially be useful for EGFR-TKI 
resistant patients with EGFR-mutant NSCLC, and 
optional for EGFR-TKI sensitive patients. Further studies 
are warranted to confirm the potential clinical significance 
of PD-1/PD-L1 inhibition in EGFR-mutant NSCLC 
treated with EGFR-TKIs. (p. 910)
Chen et al. evaluated the relationship between programmed death-
ligand 1 (PD-L1) and EGFR activation, as well as the molecular 
mechanism of PD-L1 regulation by EGFR activation in non-small 
cell lung cancer (NSCLC). A series of molecular techniques 
were utilized to dissect the PD-L1 regulatory pathway, immune 
suppression by EGFR activation and immune reactivation by EGFR-
TKIs and/or PD-1 inhibition in tumor cells and human peripheral 
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survival or time to recurrence in 336 consecutive patients 
with stage I non-small cell lung cancer (NSCLC) 
within 90 days before surgery. With a mean maximum 
standardized uptake values (SUVmax) of 9.2 +/- 6.9, 
the hazard or risk of dying and recurrence increased 
with an increase in SUVmax (p=0.0008 and p=0.024, 
respectively). The results indicate that preoperative FDG 
uptake in the primary tumor of patients with stage I 
NSCLC is correlated with overall survival and time to 
recurrence. The findings could help stratify these patients 
and identify those suitable for more aggressive therapy 
post-surgery. (p. 897)
•	 FDG uptake on Positron 
emission Tomography 
Correlates with survival 
and Time to Recurrence in 
Patients with stage I non-
small Cell Lung Cancer
Gainor JF, Tan DS, De Pas T, et al. Progression-free 
and overall survival in ALK-positive NSCLC patients 
treated with sequential crizotinib and ceritinib. Clin 
Cancer Res, doi:10.1158/1078-0432.ccr-14–3009 (2015).
ReseARCh WATCh
•	 Progression-Free and 
Overall survival in ALK-
Positive nsCLC Patients 
Treated with sequential 
Crizotinib and Ceritinib
ceritinib demonstrated a median combined PFS of 17.4 
months. ALK resistance mutations did not significantly 
affect PFS on ceritinib as shown in the post-crizotinib/
pre-ceritinib biopsies of 23 patients (mPFS 5.8 
months with mutation versus 6.5 months without 
mutations; P=0.510). Median overall survival was 49.4 
months in the overall study population. The findings 
suggested significant anti-tumor activity of ceritinib 
in ALK-positive NSCLC, even with immediate prior 
crizotinib treatment. This also warrants further studies 
to determine the influence of specific ALK resistance 
mutations on duration of response to ceritinib.
In this retrospective study, a cohort of 73 ALK-positive patients who 
received both crizotinib and ceritinib were evaluated for the clinical 
outcome of sequential treatment with these agents at 4 institutions. 
The analysis showed a median progression-free survival (mPFS) 
of 8.2 months on crizotinib and 7.8 months on ceritinib, with a 
median interval of 25 days from discontinuing crizotinib to starting 
ceritinib. Similar mPFS of 7.8 months on ceritinib was observed in 
patients with no interval therapies between crizotinib and ceritinib 
(n=53). Those who had sequential treatment with crizotinib and 
•	 Mutational Landscape 
Determines sensitivity to 
PD-1 Blockade in non–
small Cell Lung Cancer
SCN8A, and SLIT3. Higher neoantigen burden was 
associated with DCB and improved median PFS (14.5 
versus 3.5 months; P=0.002). Analysis from one patient 
with exceptional response to the an-PD-1 therapy 
demonstrated neoantigen-specific CD8+ T cell responses 
correlated with tumor regression, indicating autologous 
T cell responses against cancer neoantigens in response 
to anti-PD-1 therapy. This study demonstrated that 
clinical efficacy strongly correlates with increased 
nonsynonymous mutation burden in NSCLCs treated 
with pembrolizumab, as well as with a molecular 
smoking signature, DNA repair mutations, and the 
neoantigen burden. The findings suggested that the lung 
cancer genomic profile dictates response to anti-PD-1 
therapy, and could guide the use of these agents in 
the clinic. The observation of neoantigen-specific T 
cell reactivity mediated by anti-PD-1 therapy in the 
peripheral blood compartment warrants further studies 
for blood-based assay development to monitor response.
To evaluate the hypothesis that the mutational landscape of non-
small cell lung cancer (NSCLC) could affect response to antibody 
therapy targeting programmed cell death-1 (PD-1), Rizvi et al. 
sequenced the exomes of NSCLCs treated with pembrolizumab 
(anti-PD-1 antibody) in 2 independent cohorts (n=16 and n=18, 
respectively), as well as their paired normal DNA. The results 
showed that higher somatic nonsynonymous mutation burden was 
associated with clinical efficacy: improved objective response rate 
(ORR, 63% versus 0%; P=0.03), median progression-free survival 
(PFS, 14.5 versus 3.7 months; P=0.01; hazard ratio = 0.19), and 
durable clinical benefit (DCB, P=0.02 and 0.04 in both cohorts). 
Compared to the never-smoking signature, the molecular smoking 
signature was associated with significantly improved efficacy: ORR 
56% versus 17%, P=0.03; DCB rate 77% versus 22%, P=0.004; 
median PFS (not reached versus 3.5 months, P=0.0001) while 
self-reported smoking history did not. DCB was also correlated 
with deleterious mutations in the DNA repair and replication 
pathway, including POLR2A, KEAP1, PAPPA2, PXDNL, RYR1, 
This retrospective study assessed the relationship between 
fluorodeoxyglucose (FDG) uptake of the primary tumor at the time 
of diagnosis by positron emission tomography (PET) and overall 
Rizvi NA, Hellmann MD, Snyder A, et al. Mutational 
landscape determines sensitivity to PD-1 blockade in 
non–small cell lung cancer. Science 2015;348:124–128.
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•	 smoking and Mortality—
Beyond established Causes
(relative risk [RR] = 2.0), intestinal ischemia (RR = 6.0), 
hypertensive heart disease (RR = 2.4), infections  
(RR = 2.3), various respiratory diseases (RR = 2.0), 
breast cancer (RR = 1.3), and prostate cancer (RR = 1.4). 
Former smokers showed declining RR for each of these 
causes with increasing number of years since quitting. 
This study identified new causes for smoking-attributable 
mortality from the study population, which warrants 
further investigation and future consideration in studies of 
smoking mortality burden.
Carter BD, Abnet CC, Feskanich D, et al. Smoking 
and mortality--beyond established causes. NEJM 
2015;372:631–640.
The authors sought to investigate additional diseases caused by 
cigarette smoking, beyond the established estimates of smoking-
attributable mortality in the United States. Data from 5 contemporary 
U.S. cohort studies (421,378 men and 532,651 women aged ≥ 55 
years) were pooled, in which individuals were followed up from 2000 
to 2011. There were 16,475 deaths among current smokers out of the 
overall 181,377 deaths. Current smokers had an approximately 17% 
of excess mortality associated with causes not currently recognized 
as attributable to smoking, including deaths from renal failure 
neWs In BRIeF
•	 Combination Cell-Gene 
Therapy for Lung Cancer 
to be Tested in uK Patients
The Medical Research Council has granted a £2 million 
Biomedical Catalyst funding for a clinical trial in 
NHS lung cancer patients to evaluate a novel therapy 
that incorporates the Tumor Necrosis Factor related 
Apoptosis-Inducing Ligand (TRAIL) gene into donor 
bone marrow stem cells, which would trigger apoptosis 
in only cancer cells, sparing the healthy cells. The 
trial led by Professor Sam Janes of University College 
London will involve 56 patients with metastatic lung 
cancer. Each of them will be given almost a billion cells 
over 3 infusions, 3 weeks apart (injected a day post-
chemotherapy). Preclinical studies have demonstrated 
complete tumor elimination or significant tumor 
regression from the therapy. Its first-in-human study will 
begin this year.
Image source: NIH
•	 Decline in Proportion 
of Lung Cancer Patients 
Meeting screening Criteria
1984 and 2011 in Olmsted County, Minnesota. The 
analysis of 1,351 patients revealed the decline from 
56.8% (1984–1990) to 43.3% (2005–2011) (P<0.001 
for trend), in both women (P=0.005) and men (P=0.03). 
During the study period, there was an increase in the 
proportion of lung cancer patients who were former 
smokers (P =0.002 for trend), decrease in current 
smokers (P=0.003 for trend), increase in those with < 30 
pack-years (P<0.001 for tend), decrease in those with ≥ 
30 pack-years (P<0.001 for tend). Former smokers who 
had quit for < 15 years decreased while those for ≥ 15 
years increased (Both P<0.001 for tend). The authors 
concluded that the decline in the proportion of patients 
meeting screening criteria could indicate an increasing 
number of lung cancer patients would not have been 
eligible for screening, and therefore would require more 
sensitive screening criteria while justifying potential 
harm from LDCT.
Image source: US Navy | Kevin H. Tierney
A retrospective study published in JAMA reported a significant 
decline in the proportion of patients with lung cancer who would 
have met the U.S. Preventive Services Task Force screening 
requirements for low-dose computed tomography (LDCT) between 
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•	 The Impact of Regional 
economic Reliance on 
the Tobacco Industry on 
Current smoking in China
participants were conducted to obtain information on 
smoking status and socio-demographic characteristics 
while data from a national database was used to retrieve 
other contextual factors. Of the 31 municipalities/
provinces in China, a total of 20,601 people from 27 
cities within 26 municipalities/provinces participated 
in the study. Smoking prevalence was 31.3% overall, 
highest in Yinchuan City in Ningxia Province (49.8%) 
and lowest in Shanghai (21.6%). The analysis showed 
that people residing in provinces with the greatest 
rate of cigarette production had a higher likelihood of 
being a current smoker compared with those living in 
provinces with the lowest production (p<0.001). The 
findings reiterated the need for restriction and regulation 
in cigarette production and marketing in China.
As far as tobacco control goes, the interaction with the 
TPPA is complex. The TPPA has implications for other 
areas of health policy, including access to medicines, 
but for this column, the focus is on tobacco control. 
The member countries have varying approaches and 
levels of commitment to tobacco control. Australia, New 
Zealand, Malaysia, Brunei and Singapore have strong 
smoke-free goals and policies (as does Thailand as an 
interested party). Canada has a mix of strong policy 
and past capitulation to investor-state dispute settlement 
threats (ISDS provisions - covered in previous columns). 
Chile, Peru, and Mexico’s approaches are less clear. The 
USA is the only member that does not ratify the FCTC. 
Vietnam has a state-owned tobacco producer. Japan’s 
government is a major shareholder in Japan Tobacco 
Inc, which has just launched legal action against 
Ireland’s plan packaging legislation. As an example of 
how Big Tobacco can use (or abuse) legal processes and 
trade agreements to oppose internal tobacco control 
policy, Kelsey summarizes Australia’s experience after 
neWs FROM The IAsLC 
TOBACCO COnTROL 
COMMITTee
•	 The Trans-Pacific Partnership 
Agreement
This column has referred to the Trans Pacific Partnership 
Agreement (TPPA) on prior occasions and for tobacco control, 
its influence may be profound. A recent Med J Aust editorial has 
identified a number of areas of concern for doctors and recent 
publications support the enquiries of anyone who is interested. To 
recap, the TPPA is a relatively new type of trade agreement that 
emerged just before the global financial crisis. It has been described 
as “more than just a trade negotiation” because it “has the capacity 
to reach further into domestic economies and…policy settings than 
a conventional trade agreement”. How did it start? Well, negotiators 
from eight countries (seven full members and one associate member 
- see below) started talks in 2010. In fact it started before that with 
the Trans Pacific Strategic Economic Partnership between Chile, 
New Zealand, Singapore and Brunei in 2005 – this agreement 
is known as the “P4”, a term that crops up now and again. As in 
the table below, the TPPA is still developing and still acquiring 
new, interested parties. To those experienced in following trade 
and investment law developments, the novelty in the TPPA lies in 
what Kelsey describes as “frameworks for…. domestic regulation 
[that mandate] engagement with interested commercial interests 
[and introduce] a general presumption in favor of light-handed 
regulation”.
TPPA Membership
Date Members (full) Members (associate)/ 
Interested countries
March  
2010
Australia, Brunei 
Darussalam, Chile, 
New Zealand, Peru, 
Singapore, USA
Vietnam
December 
2010
Australia, Brunei 
Darussalam, Chile, 
New Zealand, Peru, 
Singapore, USA, 
Vietnam, Malaysia
December 
2012
Above + Canada, Mexico
Now Above + Canada, 
Mexico, Japan
Thailand – expressed 
interest
The study by Yang et al. published in Health & Place provided 
a preliminary evaluation of the impact of provincial economic 
reliance on the tobacco industry and individual characteristics on 
being a current smoker in China. In-person interviews with the 
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passing the Tobacco Plain Packaging Acct in 2011. 
This internal, domestic tobacco control legislation was 
opposed on three fronts:
-  Four tobacco companies alleged that the Act 
breached Australia’s own constitution; the High 
Court of Australia rejected this claim in December 
2012 (when the Act became law).
-  Ukraine initiated a WTO dispute (a process to which 
tobacco companies have admitted the provision of 
legal support).
-  Philip Morris Asia lodged an ISDS proceeding 
to oppose this under the Australia-Hong Kong 
Bilateral Investment Treaty 1993 (not the TPPA but 
infused with similar ISDS provisions).
The MJA editorial calls for doctors to oppose 
“health-damaging provisions”, to argue for wording that 
protects public health and to seek “greater transparency 
in…negotations” with the spectre placed in front of 
us by Kelsey that without external pressure the TPPA 
could hand to corporate interests “a structured role…. to 
interfere in countries’ domestic policy process”.
Kelsey J. The Trans-Pacific Partnership Agreement: 
a gold-plated gift to the global tobacco industry. Am J 
Law Med 2013;39:237–264.
Thow AM. What doctors should know about the 
Trans-Pacific Partnership Agreement. Med J Aust 
2015;202:165–166.
•	 Plain Packaging update
Big Tobacco Tactics
Ireland passed plain packaging legislation on February 26, 2015, signed 
into law on March 10 (this column, May 2015). The Independent 
reports that Japan Tobacco International has launched a legal case to 
oppose this, challenging Ireland’s right to do this under EU law. The 
threat of such legal action had been reported (Reuters) even before the 
legislation was passed, making it clear (if it was not already) that Big 
Tobacco lies in wait for domestic tobacco control initiatives, ready to 
attack, oppose and legally swamp them if at all possible.
http://www.independent.ie/irish-news/politics/exclusive-major-
tobacco-firm-launches-legal-bid-to-halt-governments-controversial-
plain-packaging-measures-31106022.html
http://www.reuters.com/article/2015/02/17/
japan-tobacco-ireland-idUSL5N0VR2QF20150217
“Plain packaging has delivered on its aim to reduce 
appeal of packs, particularly with adolescents and young 
adults.
There was no evidence of an increase in the 
consumption of illicit “cheap white” cigarettes.
The impact of plain packaging extends beyond 
expectation with studies suggesting the initiative 
encourages thinking about quitting and quit attempts.”
http://www.cancervic.org.au/about/media-
releases/2015-media-releases/march-2015/australias-
plain-packaging-is-working.html
Australia – It’s Working
Implementation and evaluation of the Australian 
tobacco plain packaging policy Tob Control 2015 Apr; 
24(Suppl 2): 1–100.
The Cancer Council Victoria website reports on studies 
evaluating plain packaging since introduction to 
Australia in December 2012. The studies, published as 
a series of fourteen papers in a supplement to Tobacco 
Control, a BMJ journal, make a number of key findings 
including:
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And Now There Are Three
On March 16, the House of Lords passed plain 
packaging legislation in the UK. As reported in the 
World Intellectual Property Review Big Tobacco 
(British American Tobacco, Philip Morris International 
and Imperial Tobacco Group) has already announced 
plans for legal challenge, with the corporate affairs 
director for Philip Morris calling the move “an irrational 
and unnecessary attack on private property”. The 
regulations are due for implementation in England 
(although not Scotland, Wales or Northern Ireland) in 
2016.
http://www.worldipreview.com/news/house-of-lords-
gives-plain-packaging-the-green-light-8060
http://www.worldipreview.com/news/tobacco-
companies-threaten-legal-action-over-uk-plain-
packaging-8044
Image source: NCI
